Ocular decompression retinopathy following intracameral bevacizumab injection in a case of proliferative diabetic retinopathy with neovascular glaucoma

Indian J Ophthalmol. 2020 Jun;68(6):1206-1209. doi: 10.4103/ijo.IJO_1401_19.

Abstract

A 49-year-old diabetic female was diagnosed to have both eyes proliferative diabetic retinopathy (PDR) and neovascular glaucoma (NVG [rubeosis stage in the right eye and angle-closure stage in the left eye]). The right eye anterior and posterior segment new vessels regressed 2 weeks following intravitreal bevacizumab (IVB) injection. The left eye fundus revealed fibrovascular proliferation (FVP) for which panretinal photocoagulation (PRP) was started and subsequently intracameral bevacizumab (ICB) was injected. Following this intervention, the left eye new vessels of iris regressed but fundus showed multiple peripapillary white-centered intraretinal and subhyaloid hemorrhage suggestive of decompression retinopathy. Ocular decompression retinopathy presents as retinal hemorrhages following the acute lowering of the intraocular pressure (IOP). This case describes the rare occurrence of ocular decompression retinopathy following ICB in a case of PDR with NVG.

Keywords: Decompression retinopathy; intracameral bevacizumab; neovascular glaucoma.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / adverse effects
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Bevacizumab / adverse effects
  • Decompression
  • Diabetes Mellitus*
  • Diabetic Retinopathy* / complications
  • Diabetic Retinopathy* / diagnosis
  • Diabetic Retinopathy* / drug therapy
  • Female
  • Glaucoma, Neovascular* / diagnosis
  • Humans
  • Intraocular Pressure
  • Middle Aged
  • Retinal Diseases*
  • Vascular Endothelial Growth Factor A

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab